ARK Genomic Revolution (ARKG) is a publicly traded Financial Services sector company. As of May 21, 2026, ARKG trades at $29.45 with a market cap of $0 and a P/E ratio of 0.00. ARKG moved +5.25% today. Year to date, ARKG is -1.47%; over the trailing twelve months it is +35.07%. Its 52-week range spans $17.51 to $34.39. Rallies surfaces ARKG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Mizuho Sets $100 Target on Tempus AI, Shares Jump Over 4%: Tempus AI shares surged over 4% after Mizuho initiated coverage with an Outperform rating and set a $100 price target. The company also unveiled its HRD-RNA algorithm for detecting homologous recombination deficiency in tumors, with clinical rollout planned later this year, as earnings are slated for Feb. 24.
| Metric | Value |
|---|---|
| Price | $29.45 |
| Market Cap | $0 |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.38% |
| 52-Week High | $34.39 |
| 52-Week Low | $17.51 |
| Volume | 1.24K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
ARKG analyst coverage data. Average price target: $0.00.